Table 5.
Rates of Minor Hypoglycemia in Dual Therapy with Noninsulin Secretagoguesa
| Combination # | Drug 1 | Drug 2 | Reference | Rate for minor hypoglycemia in control group | Rate for minor hypoglycemia in treatment group | Rate ranges |
|---|---|---|---|---|---|---|
| 1 | M | T | Scott34 | M 1.2% | M + rosiglitazone 1.2% | |
| Wysham42 | M + pioglitazone 4.3% | |||||
| Pfützner43 | M + pioglitazone 1.4% | |||||
| Bolli44 | M + pioglitazone 0% | |||||
| Vlckova45 | M 0.9%b | M + pioglitazone 0.4%b | ||||
| Bergenstal46 | M 1% | M + pioglitazone 1% | ||||
| M + T = 0-4.3% | ||||||
| 2 | M | DPP-4 | Scott34 | M 1.2% | M + sitagliptin 1.2% | |
| Williams-Herman36 | Sitagliptin 3.1%b | M (or T) + sitagliptin 3.3%b | ||||
| Bergenstal46 | M + sitagliptin 3% | |||||
| Wysham42 | M + sitagliptin 0.1% | |||||
| Bolli44 | M + vildagliptin 0.3%b | |||||
| M + DPP = 0.1–3.3% | ||||||
| 3 | M | GLP-1 | Bergenstal46 | M + exenatide once-weekly 1.0% | ||
| Buse47 | M + exenatide 11% | M + liraglutide 6.2% | ||||
| Liutkus48 | M + GLP = 1–11% | |||||
| 4 | M | AGI | Rosenstock49 | M 1.6%b | M + AGI 2.6%b | |
| Jayaram50 | M + AGI 0%b | |||||
| Lin51 | M + AGI 0%b | M + AGI = 0–2.6% | ||||
| 5 | M | DA | Gaziano40 | M or sulfonylurea 0.4%b | M or sulfonylurea + bromocriptine 0.2%b | |
| M + DA = 0.2% | ||||||
| 6 | M | BAS | Zieve52 | Placebo + sulfonylurea (± M) no differenceb | Colesevelam + sulfonylurea (± M) no differenceb | |
| Bays41 | M 0% | Colesevelam + M 0.6% | ||||
| M + BAS = 0.6% | ||||||
| 7 | DPP-4 | T | Kim53 | Vildagliptin + pioglitazone 0%b | ||
| Rosenstock35 | Alogliptin + pioglitazone 3% | |||||
| Rosenstock54 | Sitagliptin 0%b | Sitagliptin + pioglitazone 1.1%b | ||||
| DPP + T = 0–3% | ||||||
| 8 | GLP-1 | T | Zinman55 | T 10.7% | GLP + T 7.1% | |
| Liutkus48 | T (or M) 1.9% | GLP + T (or M) 3.6% | ||||
| GLP + T = 3.6–7.1% | ||||||
| 9 | AGI | T | Vlckova45 | AGI + pioglitazone 0.3%b | ||
| AGI + T = 0.3% |
a
M, metformin; T, thiazolidinedione.
b
Not defined as major versus minor.